STML - Your Daily Pharma Scoop: Redhill Receives NoA Regeneron Gets CRL Stemline NDA Under Review
Stocks in News: RDHL, REGN
RedHill Bio nabs U.S. patent covering RHB-104 and RHB-204
Discussion: RedHill Biopharma (RDHL) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The notice allows the patent to be valid until at least 2029. Apart from Crohn’s Disease, the company has diverse program pipeline. The program includes other indications such as H. Pylori infection, migraine, and nontuberculous mycobacteria (NTM) infections.
RedHill Biopharma’s (RDHL) RB-104 recently succeeded in Phase 3 clinical trial on Crohn's